Evidence Snapshot

Adrenomedullin receptor, AM2; CALCRL/RAMP3

CHEMBL2111191 PROTEIN COMPLEX Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:15Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:31 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2111191

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Adrenomedullin receptor, AM2; CALCRL/RAMP3 as ChEMBL target CHEMBL2111191, mapped to UniProt Q16602. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Adrenomedullin receptor, AM2; CALCRL/RAMP3

PROTEIN COMPLEX · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2111191

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

Q16602

Calcitonin gene-related peptide type 1 receptor

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Adrenomedullin receptor, AM2; CALCRL/RAMP3 matters

As of 2026-09-13

Adrenomedullin receptor, AM2; CALCRL/RAMP3 is reviewed as Calcitonin gene-related peptide type 1 receptor (UniProt Q16602); the current evidence base includes 1 approved drug, 12 compounds, and 3 assays, with lead potency reaching pChEMBL 7.9.

Protein context

Calcitonin gene-related peptide type 1 receptor

Calcitonin gene-related peptide type 1 receptor Sequence length is 461 aa.

Review this target as Adrenomedullin receptor, AM2; CALCRL/RAMP3, mapped to UniProt Q16602. ChEMBL maps the protein component as Calcitonin gene-related peptide type 1 receptor. Sequence length is 461 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q16602 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 12 compounds, and 3 assays for this target. The dominant activity type is IC50. CHEMBL503773 is the current potency anchor at pChEMBL 7.9.

Use CHEMBL503773 as the tractability anchor when discussing potency (pChEMBL 7.9).

Activity source · ChEMBL 36 via Core Engine

1 approved pChEMBL 7.9

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Adrenomedullin receptor, AM2; CALCRL/RAMP3 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q16602, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

Total Compounds

Total Assays

Approved Drugs

IC50: 8.0, KI: 1.0, EC50: 1.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL503773	7.9	IC50	—
No preferred name CHEMBL509329	7.0	IC50	—
No preferred name CHEMBL2103758	6.8	EC50	Approved
No preferred name CHEMBL525571	6.6	IC50	—
No preferred name CHEMBL525039	6.5	IC50	—